Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

In an effort to pinpoint potential genetic risk factors for schizophrenia, research groups worldwide have published over 1,000 genetic association studies with largely inconsistent results. To facilitate the interpretation of these findings, we have created a regularly updated online database of all published genetic association studies for schizophrenia ('SzGene'). For all polymorphisms having genotype data available in at least four independent case-control samples, we systematically carried out random-effects meta-analyses using allelic contrasts. Across 118 meta-analyses, a total of 24 genetic variants in 16 different genes (APOE, COMT, DAO, DRD1, DRD2, DRD4, DTNBP1, GABRB2, GRIN2B, HP, IL1B, MTHFR, PLXNA2, SLC6A4, TP53 and TPH1) showed nominally significant effects with average summary odds ratios of ∼1.23. Seven of these variants had not been previously meta-analyzed. According to recently proposed criteria for the assessment of cumulative evidence in genetic association studies, four of the significant results can be characterized as showing 'strong' epidemiological credibility. Our project represents the first comprehensive online resource for systematically synthesized and graded evidence of genetic association studies in schizophrenia. As such, it could serve as a model for field synopses of genetic associations in other common and genetically complex disorders.

[1]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[2]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[3]  Lin He,et al.  Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: A HuGE review and meta-analysis , 2007, Genetics in Medicine.

[4]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[5]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[6]  Nikolaos A Patsopoulos,et al.  Uncertainty in heterogeneity estimates in meta-analyses , 2007, BMJ : British Medical Journal.

[7]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[8]  Michael J Owen,et al.  Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? , 2005, Schizophrenia bulletin.

[9]  E. Gershon,et al.  Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia , 2002, Molecular Psychiatry.

[10]  M. Flaum,et al.  Spurious precision: procedural validity of diagnostic assessment in psychotic disorders. , 1995, The American journal of psychiatry.

[11]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[12]  Alan A. Wilson,et al.  Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. , 2004, The American journal of psychiatry.

[13]  Daniel R Weinberger,et al.  Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. , 2004, Archives of general psychiatry.

[14]  Nathaniel Rothman,et al.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.

[15]  Ammarin Thakkinstian,et al.  Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration , 2006 .

[16]  M. Munafo,et al.  Association of the NRG1 gene and schizophrenia: a meta-analysis , 2006, Molecular Psychiatry.

[17]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[18]  J. Ioannidis,et al.  An exploratory test for an excess of significant findings , 2007, Clinical trials.

[19]  P. Spano,et al.  The NMDA/D1 receptor complex as a new target in drug development. , 2006, Current topics in medicinal chemistry.

[20]  Thomas A Trikalinos,et al.  'Racial' differences in genetic effects for complex diseases , 2004, Nature Genetics.

[21]  Christoph Lange,et al.  PBAT: tools for family-based association studies. , 2004, American journal of human genetics.

[22]  K. Mossman.  The Wellcome Trust Case Control Consortium, U.K. , 2008 .

[23]  Roger M Harbord,et al.  A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints , 2006, Statistics in medicine.

[24]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[25]  J. Hoh,et al.  Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. , 2006, Human molecular genetics.

[26]  Siobhan M. Dolan,et al.  Assessment of cumulative evidence on genetic associations: interim guidelines. , 2008, International journal of epidemiology.

[27]  S. McGurk,et al.  Schizophrenia , 2004, The Lancet.

[28]  Leena Peltonen,et al.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. , 2003, American journal of human genetics.

[29]  J. Brooks.  Why most published research findings are false: Ioannidis JP, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece , 2008 .

[30]  L. DeLisi,et al.  Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia , 2006, Molecular Psychiatry.

[31]  K. Arima,et al.  Failure to confirm an association between the PLXNA2 gene and schizophrenia in a Japanese population , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  Thomas A Trikalinos,et al.  Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. , 2005, Journal of clinical epidemiology.

[33]  S. Purcell,et al.  Contribution of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms to Negative Symptoms in Schizophrenia , 2008, Biological Psychiatry.

[34]  M J Owen,et al.  Schizophrenia: genes at last? , 2005, Trends in genetics : TIG.

[35]  Paolo Vineis,et al.  A road map for efficient and reliable human genome epidemiology , 2006, Nature Genetics.

[36]  R Kucherlapati,et al.  Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia , 2007, Molecular Psychiatry.

[37]  F. Gabreëls,et al.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? , 1998, American journal of human genetics.

[38]  P. Sullivan,et al.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. , 2003, Archives of general psychiatry.

[39]  I. Olkin,et al.  The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.